Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy

Jong Ho Kim, Yoo Shin Kim, Kyeongsoon Park, Eunah Kang, Seulki Lee, Hae Yun Nam, Kwang Meyung Kim, Jae Hyung Park, Dae Yoon Chi, Rang Woon Park, In-San Kim, Kuiwon Choi, Ick Chan Kwon

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

Antiangiogenic peptide drugs have received much attention in the fields of tumor therapy and tumor imaging because they show promise in the targeting of integrins such as αvβ3 on angiogenic endothelial cells. However, systemic antiangiogenic peptide drugs have short half-lives in vivo, resulting in fast serum clearance via the kidney, and thus the therapeutic effects of such drugs remain modest. In this study, we prepared self-assembled glycol chitosan nanoparticles and explored whether this construct might function as a prolonged and sustained drug delivery system for RGD peptide, used as an antiangiogenic model drug in cancer therapy. Glycol chitosan hydrophobically modified with 5β-cholanic acid (HGC) formed nanoparticles with a diameter of 230 nm, and RGD peptide was easily encapsulated into HGC nanoparticles (yielding RGD-HGC nanoparticles) with a high loading efficiency (>85%). In vitro work demonstrated that RGD-HGC showed prolonged and sustained release of RGD, lasting for 1 week. RGD-HGC also inhibited HUVEC adhesion to a βig-h3 protein-coated surface, indicating an antiangiogenic effect of the RGD peptide in the HGC nanoparticles. In an in vivo study, the antiangiogenic peptide drug formulation of RGD-HGC markedly inhibited bFGF-induced angiogenesis and decreased hemoglobin content in Matrigel plugs. Intratumoral administration of RGD-HGC significantly decreased tumor growth and microvessel density compared to native RGD peptide injected either intravenously or intratumorally, because the RGD-HGC formulation strongly enhanced the antiangiogenic and antitumoral efficacy of RGD peptide by affording prolonged and sustained RGD peptide delivery locally and regionally in solid tumors.

Original languageEnglish
Pages (from-to)1920-1930
Number of pages11
JournalBiomaterials
Volume29
Issue number12
DOIs
Publication statusPublished - 2008 Apr 1
Externally publishedYes

Fingerprint

Glycols
Chitosan
Nanoparticles
Peptides
Tumors
Pharmaceutical Preparations
Neoplasms
Therapeutics
Drug Compounding
Endothelial cells
Therapeutic Uses
Drug Delivery Systems
Microvessels
Integrins
arginyl-glycyl-aspartic acid
glycol-chitosan
Membrane Proteins
Hemoglobins
Adhesion
Endothelial Cells

Keywords

  • Antiangiogenic peptide drugs
  • Cancer therapy
  • Drug delivery system
  • Glycol chitosan nanoparticles

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering

Cite this

Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. / Kim, Jong Ho; Kim, Yoo Shin; Park, Kyeongsoon; Kang, Eunah; Lee, Seulki; Nam, Hae Yun; Kim, Kwang Meyung; Park, Jae Hyung; Chi, Dae Yoon; Park, Rang Woon; Kim, In-San; Choi, Kuiwon; Kwon, Ick Chan.

In: Biomaterials, Vol. 29, No. 12, 01.04.2008, p. 1920-1930.

Research output: Contribution to journalArticle

Kim, Jong Ho ; Kim, Yoo Shin ; Park, Kyeongsoon ; Kang, Eunah ; Lee, Seulki ; Nam, Hae Yun ; Kim, Kwang Meyung ; Park, Jae Hyung ; Chi, Dae Yoon ; Park, Rang Woon ; Kim, In-San ; Choi, Kuiwon ; Kwon, Ick Chan. / Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. In: Biomaterials. 2008 ; Vol. 29, No. 12. pp. 1920-1930.
@article{19ba80032d8c43b0a142448651faceff,
title = "Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy",
abstract = "Antiangiogenic peptide drugs have received much attention in the fields of tumor therapy and tumor imaging because they show promise in the targeting of integrins such as αvβ3 on angiogenic endothelial cells. However, systemic antiangiogenic peptide drugs have short half-lives in vivo, resulting in fast serum clearance via the kidney, and thus the therapeutic effects of such drugs remain modest. In this study, we prepared self-assembled glycol chitosan nanoparticles and explored whether this construct might function as a prolonged and sustained drug delivery system for RGD peptide, used as an antiangiogenic model drug in cancer therapy. Glycol chitosan hydrophobically modified with 5β-cholanic acid (HGC) formed nanoparticles with a diameter of 230 nm, and RGD peptide was easily encapsulated into HGC nanoparticles (yielding RGD-HGC nanoparticles) with a high loading efficiency (>85{\%}). In vitro work demonstrated that RGD-HGC showed prolonged and sustained release of RGD, lasting for 1 week. RGD-HGC also inhibited HUVEC adhesion to a βig-h3 protein-coated surface, indicating an antiangiogenic effect of the RGD peptide in the HGC nanoparticles. In an in vivo study, the antiangiogenic peptide drug formulation of RGD-HGC markedly inhibited bFGF-induced angiogenesis and decreased hemoglobin content in Matrigel plugs. Intratumoral administration of RGD-HGC significantly decreased tumor growth and microvessel density compared to native RGD peptide injected either intravenously or intratumorally, because the RGD-HGC formulation strongly enhanced the antiangiogenic and antitumoral efficacy of RGD peptide by affording prolonged and sustained RGD peptide delivery locally and regionally in solid tumors.",
keywords = "Antiangiogenic peptide drugs, Cancer therapy, Drug delivery system, Glycol chitosan nanoparticles",
author = "Kim, {Jong Ho} and Kim, {Yoo Shin} and Kyeongsoon Park and Eunah Kang and Seulki Lee and Nam, {Hae Yun} and Kim, {Kwang Meyung} and Park, {Jae Hyung} and Chi, {Dae Yoon} and Park, {Rang Woon} and In-San Kim and Kuiwon Choi and Kwon, {Ick Chan}",
year = "2008",
month = "4",
day = "1",
doi = "10.1016/j.biomaterials.2007.12.038",
language = "English",
volume = "29",
pages = "1920--1930",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "12",

}

TY - JOUR

T1 - Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy

AU - Kim, Jong Ho

AU - Kim, Yoo Shin

AU - Park, Kyeongsoon

AU - Kang, Eunah

AU - Lee, Seulki

AU - Nam, Hae Yun

AU - Kim, Kwang Meyung

AU - Park, Jae Hyung

AU - Chi, Dae Yoon

AU - Park, Rang Woon

AU - Kim, In-San

AU - Choi, Kuiwon

AU - Kwon, Ick Chan

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Antiangiogenic peptide drugs have received much attention in the fields of tumor therapy and tumor imaging because they show promise in the targeting of integrins such as αvβ3 on angiogenic endothelial cells. However, systemic antiangiogenic peptide drugs have short half-lives in vivo, resulting in fast serum clearance via the kidney, and thus the therapeutic effects of such drugs remain modest. In this study, we prepared self-assembled glycol chitosan nanoparticles and explored whether this construct might function as a prolonged and sustained drug delivery system for RGD peptide, used as an antiangiogenic model drug in cancer therapy. Glycol chitosan hydrophobically modified with 5β-cholanic acid (HGC) formed nanoparticles with a diameter of 230 nm, and RGD peptide was easily encapsulated into HGC nanoparticles (yielding RGD-HGC nanoparticles) with a high loading efficiency (>85%). In vitro work demonstrated that RGD-HGC showed prolonged and sustained release of RGD, lasting for 1 week. RGD-HGC also inhibited HUVEC adhesion to a βig-h3 protein-coated surface, indicating an antiangiogenic effect of the RGD peptide in the HGC nanoparticles. In an in vivo study, the antiangiogenic peptide drug formulation of RGD-HGC markedly inhibited bFGF-induced angiogenesis and decreased hemoglobin content in Matrigel plugs. Intratumoral administration of RGD-HGC significantly decreased tumor growth and microvessel density compared to native RGD peptide injected either intravenously or intratumorally, because the RGD-HGC formulation strongly enhanced the antiangiogenic and antitumoral efficacy of RGD peptide by affording prolonged and sustained RGD peptide delivery locally and regionally in solid tumors.

AB - Antiangiogenic peptide drugs have received much attention in the fields of tumor therapy and tumor imaging because they show promise in the targeting of integrins such as αvβ3 on angiogenic endothelial cells. However, systemic antiangiogenic peptide drugs have short half-lives in vivo, resulting in fast serum clearance via the kidney, and thus the therapeutic effects of such drugs remain modest. In this study, we prepared self-assembled glycol chitosan nanoparticles and explored whether this construct might function as a prolonged and sustained drug delivery system for RGD peptide, used as an antiangiogenic model drug in cancer therapy. Glycol chitosan hydrophobically modified with 5β-cholanic acid (HGC) formed nanoparticles with a diameter of 230 nm, and RGD peptide was easily encapsulated into HGC nanoparticles (yielding RGD-HGC nanoparticles) with a high loading efficiency (>85%). In vitro work demonstrated that RGD-HGC showed prolonged and sustained release of RGD, lasting for 1 week. RGD-HGC also inhibited HUVEC adhesion to a βig-h3 protein-coated surface, indicating an antiangiogenic effect of the RGD peptide in the HGC nanoparticles. In an in vivo study, the antiangiogenic peptide drug formulation of RGD-HGC markedly inhibited bFGF-induced angiogenesis and decreased hemoglobin content in Matrigel plugs. Intratumoral administration of RGD-HGC significantly decreased tumor growth and microvessel density compared to native RGD peptide injected either intravenously or intratumorally, because the RGD-HGC formulation strongly enhanced the antiangiogenic and antitumoral efficacy of RGD peptide by affording prolonged and sustained RGD peptide delivery locally and regionally in solid tumors.

KW - Antiangiogenic peptide drugs

KW - Cancer therapy

KW - Drug delivery system

KW - Glycol chitosan nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=39749105878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749105878&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2007.12.038

DO - 10.1016/j.biomaterials.2007.12.038

M3 - Article

VL - 29

SP - 1920

EP - 1930

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 12

ER -